Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Milestone Pharmaceuticals has received an average consensus recommendation of "Hold" from five brokerages, with three holding and two buying ratings.
• The average twelve-month price target for Milestone Pharmaceuticals is $4.50, with Wells Fargo setting a target of $4.00 and HC Wainwright at $5.00.
• The company recently reported earnings of ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18).

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been given an average rating of "Hold" by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $4.50.

A number of equities analysts have weighed in on MIST shares. Wells Fargo & Company assumed coverage on Milestone Pharmaceuticals in a research report on Thursday. They set an "overweight" rating and a $4.00 price target on the stock. HC Wainwright raised Milestone Pharmaceuticals to a "buy" rating and set a $5.00 target price on the stock in a research report on Thursday, June 5th.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently made changes to their positions in MIST. Northern Trust Corp lifted its stake in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after purchasing an additional 30,772 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth $73,000. Toronto Dominion Bank bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth $1,770,000. XTX Topco Ltd lifted its stake in Milestone Pharmaceuticals by 52.7% during the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after purchasing an additional 17,950 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in Milestone Pharmaceuticals during the first quarter worth $74,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $1.71 on Thursday. The firm has a market cap of $145.33 million, a price-to-earnings ratio of -2.04 and a beta of 0.60. The stock's 50-day moving average is $1.70 and its 200-day moving average is $1.55. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $2.75. The company has a debt-to-equity ratio of 4.06, a current ratio of 4.97 and a quick ratio of 4.97.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Equities analysts predict that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.